Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein

Oncology Reports

Volumn 17, Issue 4, 2007, Pages 969-976

  Shi, Zhi ^a,b   Liang, Yong Ju ^a   Chen, Zhe Sheng ^b   Wang, Xiao Hong ^a   Ding, Yan ^a   Chen, Li Ming ^a,b   Fu, Li Wu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b ST JOHN'S UNIVERSITY   (United States)

Author keywords

IAPs; MDR; P gp; Survivin; Tumor; XIAP

Indexed keywords

ANTINEOPLASTIC AGENT; BIRC4 PROTEIN, HUMAN; BIRC5 PROTEIN, HUMAN; GLYCOPROTEIN P; MICROTUBULE ASSOCIATED PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; BREAST TUMOR; DOWN REGULATION; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; UP-REGULATION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 34249952126     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.4.969     Document Type: Article

References (44)

1. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002. (Pubitemid 37328807)
2. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
3. Kruh GD: Introduction to resistance to anticancer agents. Oncogene 22: 7262-7264, 2003.
4. Smyth MJ, Krasovskis E, Sutton VR and Johnstone RW: The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 95: 7024-7029, 1998.
5. Johnstone RW, Cretney E and Smyth MJ: P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93: 1075-1085, 1999. (Pubitemid 29067874)
6. Ruth AC and Roninson IB: Effects of the multidrug transporter P-glycoprotein on cellular responses to ionizing radiation. Cancer Res 60: 2576-2578, 2000. (Pubitemid 30318226)
7. Nachmias B, Ashhab Y and Ben-Yehuda D: The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 14: 231-243, 2004. (Pubitemid 38824584)
8. Vaux DL and Silke J: IAPs - the ubiquitin connection. Cell Death Differ 12: 1205-1207, 2005. (Pubitemid 41195106)
9. Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22: 8581-8589, 2003.
10. Rothe M, Pan MG, Henzel WJ, Ayres TM and Goeddel DV: The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83: 1243-1252, 1995. (Pubitemid 26007814)
11. Notarbartolo M, Cervello M, Dusonchet L, Cusimano A and D'Alessandro N: Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel antiapoptosis factors IAP (inhibitory of apoptosis proteins). Cancer Lett 180: 91-101, 2002. (Pubitemid 34242969)
12. Notarbartolo M, Cervello M, Poma P, et al: Expression of the IAPs in multidrug resistant tumor cells. Oncol Rep 11: 133-136, 2004.
13. Lima RT, Martins LM, Guimaraes JE, Sambade C and Vasconcelos MH: Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 11: 309-316, 2004. (Pubitemid 38586086)
14. Chawla-Sarkar M, Bae SI, Reu FJ, et al: Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 11: 915-923, 2004. (Pubitemid 39139750)
15. Amarzguioui M: Improved siRNA-mediated silencing in refractory adherent cell lines by detachment and transfection in suspension. Biotechniques 36: 766-768, 2004.
16. Shi Z, Liang YJ, Chen ZS, et al: Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther 5: 39-47, 2006. (Pubitemid 43234976)
17. Wang XW, Ding Y, Liang YJ, et al: Enhancement of FG020326 on sensitivity of MCF-7/ADR cells to taxotere via enhancing activation of caspase-8 and caspase-3. Ai Zheng 23: 1379-1385, 2004.
18. Chu ZL, McKinsey TA, Liu L, et al: Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci USA 94: 10057-10062, 1997. (Pubitemid 27406993)
19. Stehlik C, de Martin R, Kumabashiri I, et al: Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med 188: 211-216, 1998. (Pubitemid 28328620)
20. Kawakami H, Tomita M, Matsuda T, et al: Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax. Int J Cancer 115: 967-974, 2005. (Pubitemid 40791839)
21. Mirza A, McGuirk M, Hockenberry TN, et al: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21: 2613-2622, 2002. (Pubitemid 34478319)
22. Hoffman WH, Biade S, Zilfou JT, Chen J and Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277: 3247-3257, 2002. (Pubitemid 34953189)
23. Zhang T, Otevrel T, Gao Z, et al: Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61: 8664-8667, 2001. (Pubitemid 34013874)
24. Asanuma H, Torigoe T, Kamiguchi K, et al: Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 65: 11018-11025, 2005. (Pubitemid 41713372)
25. Xia W, Bisi J, Strum J, et al: Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res 66: 1640-1647, 2006. (Pubitemid 43259948)
26. Carter BZ, Mak DH, Schober WD, et al: Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood 107: 1555-1563, 2006. (Pubitemid 43242394)
27. Gritsko T, Williams A, Turkson J, et al: Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12: 11-19, 2006. (Pubitemid 43166170)
28. Sommer KW, Schamberger CJ, Schmidt GE, Sasgary S and Cerni C: Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene 22: 4266-4280, 2003. (Pubitemid 36876247)
29. Zastawny RL, Salvino R, Chen J, Benchimol S and Ling V: The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 8: 1529-1535, 1993. (Pubitemid 23189049)
30. Thottassery JV, Zambetti GP, Arimori K, Schuetz EG and Schuetz JD: p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 94: 11037-11042, 1997. (Pubitemid 27430856)
31. Kim SH, Lee SH, Kwak NH, Kang CD and Chung BS: Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter. Cancer Lett 98: 199-205, 1996.
32. Yamada T, Takaoka AS, Naishiro Y, et al: Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res 60: 4761-4766, 2000.
33. Ikeguchi M, Teeter LD, Eckersberg T, Ganapathi R and Kuo MT: Structural and functional analyses of the promoter of the murine multidrug resistance gene mdr3/mdr1a reveal a negative element containing the AP-1 binding site. DNA Cell Biol 10: 639-649, 1991.
34. Zhou J, Liu M, Aneja R, et al: Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res 66: 445-452, 2006. (Pubitemid 43166053)
35. Ogretmen B and Safa AR: Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-kappa B/p65 and c-Fos transcription factors and their interaction with the CAAT region. Biochemistry 38: 2189-2199, 1999.
36. Vilaboa NE, Galan A, Troyano A, de Blas E and Aller P: Regulation of multidrug resistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1). J Biol Chem 275: 24970-24976, 2000. (Pubitemid 30626605)
37. Ohga T, Uchiumi T, Makino Y, et al: Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 273: 5997-6000, 1998. (Pubitemid 28144673)
38. Cornwell MM and Smith DE: SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J Biol Chem 268: 19505-19511, 1993. (Pubitemid 23270733)
39. Jin S and Scotto KW: Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 18: 4377-4384, 1998. (Pubitemid 28287960)
40. Wang Z, Fukuda S and Pelus LM: Survivin regulates the p53 tumor suppressor gene family. Oncogene 23: 8146-8153, 2004. (Pubitemid 39531855)
41. Kaur S, Wang F, Venkatraman M and Arsura M: X-linked inhibitor of apoptosis (XIAP) inhibits c-Jun N-terminal kinase 1 (JNK1) activation by transforming growth factor beta1 (TGF-beta1) through ubiquitin-mediated proteosomal degradation of the TGF-beta1-activated kinase 1 (TAK1). J Biol Chem 280: 38599-38608, 2005. (Pubitemid 43853761)
42. Vaux DL and Silke J: IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 6: 287-297, 2005. (Pubitemid 40516895)
43. Zhang Z, Wu JY, Hait WN and Yang JM: Regulation of the stability of P-glycoprotein by ubiquitination. Mol Pharmacol 66: 395-403, 2004. (Pubitemid 39329238)
44. Ruefli AA, Tainton KM, Darcy PK, Smyth MJ and Johnstone RW: P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ 9: 1266-1272, 2002. (Pubitemid 35331774)